Milnacipran Hydrochloride Patent Expiration
Milnacipran Hydrochloride is Used for managing fibromyalgia. It was first introduced by Abbvie Inc
Milnacipran Hydrochloride Patents
Given below is the list of patents protecting Milnacipran Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Savella | US7994220 | Milnacipran for the long-term treatment of fibromyalgia syndrome | Sep 19, 2029 | Abbvie |
| Savella | US6602911 | Methods of treating fibromyalgia |
Jan 14, 2023
(Expired) | Abbvie |
| Savella | US6992110 | Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain |
Nov 05, 2021
(Expired) | Abbvie |
| Savella | US7888342 | Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain |
Nov 05, 2021
(Expired) | Abbvie |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Milnacipran Hydrochloride's patents.
Latest Legal Activities on Milnacipran Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Milnacipran Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 20 Mar, 2023 | US7888342 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 Jan, 2023 | US7994220 |
| Maintenance Fee Reminder Mailed Critical | 03 Oct, 2022 | US7888342 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Feb, 2019 | US7994220 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Aug, 2018 | US7888342 |
| Patent Term Extension Certificate Critical | 24 Aug, 2012 | US6602911 |
| Notice of Final Determination -Election Required | 23 Apr, 2012 | US6602911 |
| Notice of Final Determination -Election Required | 23 Apr, 2012 | US6992110 |
| Patent Issue Date Used in PTA Calculation Critical | 09 Aug, 2011 | US7994220 |
| Recordation of Patent Grant Mailed Critical | 09 Aug, 2011 | US7994220 |
Milnacipran Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Milnacipran Hydrochloride Generic API Manufacturers
Several generic applications have been filed for Milnacipran Hydrochloride. The first generic version for Milnacipran Hydrochloride was by Oryza Pharmaceuticals Inc and was approved on Jan 27, 2016. And the latest generic version is by Hetero Labs Ltd Unit V and was approved on Oct 3, 2024.
Given below is the list of companies who have filed for Milnacipran Hydrochloride generic, along with the locations of their manufacturing plants worldwide.
1. AMNEAL PHARMS
Amneal Pharmaceuticals has filed for 4 different strengths of generic version for Milnacipran Hydrochloride. Given below are the details of the strengths of this generic introduced by Amneal Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 12.5MG | tablet | Discontinued | ORAL | N/A | Apr 22, 2016 |
| 25MG | tablet | Discontinued | ORAL | N/A | Apr 22, 2016 |
| 50MG | tablet | Discontinued | ORAL | N/A | Apr 22, 2016 |
| 100MG | tablet | Discontinued | ORAL | N/A | Apr 22, 2016 |
2. HETERO LABS LTD V
Hetero Labs Ltd Unit V has filed for 4 different strengths of generic version for Milnacipran Hydrochloride. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd V.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 12.5MG | tablet | Prescription | ORAL | AB | Oct 3, 2024 |
| 25MG | tablet | Prescription | ORAL | AB | Oct 3, 2024 |
| 50MG | tablet | Prescription | ORAL | AB | Oct 3, 2024 |
| 100MG | tablet | Prescription | ORAL | AB | Oct 3, 2024 |
3. ORYZA
Oryza Pharmaceuticals Inc has filed for 4 different strengths of generic version for Milnacipran Hydrochloride. Given below are the details of the strengths of this generic introduced by Oryza.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 12.5MG | tablet | Discontinued | ORAL | N/A | Jan 27, 2016 |
| 25MG | tablet | Discontinued | ORAL | N/A | Jan 27, 2016 |
| 50MG | tablet | Discontinued | ORAL | N/A | Jan 27, 2016 |
| 100MG | tablet | Discontinued | ORAL | N/A | Jan 27, 2016 |
Manufacturing Plant Locations New
Oryza's manufacturing plants are situated in 1 country - Japan. Given below are the details of these plant locations as well as the firm names of Oryza as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| Japan |
| |||